Although ADAM17 exerts potential regulatory effects in cardiovascular diseases, including cardiac hypertrophy, coronary microvascular dysfunction, and thoracic aortic aneurysm [12, 13, 15, 38–40], its precise function in cardiac fibrosis remains unknown. Here, ADAM17 is linked to cardiac hypertrophy.